9–15 March | 16–22 March | 23–29 March | 30 March–5 April | 6–12 April | 13–19 April | 20–26 April | |
MRR (95% CI, p value) | MRR (95% CI, p value) | MRR (95% CI, p value) | MRR (95% CI, p value) | MRR (95% CI, p value) | MRR (95% CI, p value) | MRR (95% CI, p value) | |
Population mortality—including COVID-19-related attendances | 1.04 (0.96 to 1.14, 0.35) | 1.09 (1.00 to 1.19, 0.046) | 1.11 (1.02 to 1.21, 0.02) | 1.20 (1.10 to 1.31,<0.001) | 1.10 (1.00 to 1.20, 0.04) | 1.17 (1.07 to 1.27, 0.001) | 1.15 (1.05 to 1.26, 0.003) |
Population mortality—excluding COVID-19-related attendances | 1.04 (0.95 to 1.13, 0.38) | 1.06 (0.98 to 1.16, 0.16) | 1.05 (0.96 to 1.15, 0.28) | 1.10 (1.01 to 1.20, 0.03) | 1.01 (0.92 to 1.11, 0.80) | 1.10 (1.01 to 1.21, 0.04) | 1.08 (0.98 to 1.18, 0.11) |
Risk of death-in-hospital—including COVID-19-related attendances | 0.96 (0.83 to 1.11, 0.59) | 0.91 (0.79 to 1.06, 0.22) | 0.91 (0.78 to 1.06, 0.24) | 1.03 (0.89 to 1.20, 0.68) | 1.03 (0.89 to 1.20, 0.66) | 1.02 (0.88 to 1.19, 0.79) | 1.01 (0.87 to 1.18), 0.87 |
Risk of death-in-hospital—excluding COVID-19-related attendances | 0.96 (0.83 to 1.10, 0.54) | 0.85 (0.73 to 0.99, 0.04) | 0.79 (0.67 to 0.93, 0.004) | 0.86 (0.73 to 1.01, 0.06) | 0.86 (0.74 to 1.01, 0.07) | 0.92 (0.79 to 1.08, 0.31) | 0.90 (0.77 to 1.06, 0.20) |
Risk of death-in-non-psychiatric-hospital | 0.96 (0.83 to 1.11, 0.58) | 0.86 (0.74 to 1.00, 0.04) | 0.79 (0.67 to 0.93, 0.004) | 0.86 (0.73 to 1.00, 0.06) | 0.87 (0.74 to 1.01, 0.07) | 0.92 (0.79 to 1.08, 0.30) | 0.90 (0.77 to 1.06, 0.20) |
Population mortality by age | |||||||
<18 | 1.18 (0.52 to 2.69, 0.69) | 0.84 (0.30 to 2.36, 0.74) | 0.94 (0.33 to 2.68, 0.91) | 0.19 (0.02 to 1.45, 0.11) | 0.55 (0.19 to 1.65, 0.29) | 1.05 (0.44 to 2.47, 0.19) | 0.57 (0.19 to 1.74, 0.33) |
18–49 | 0.92 (0.61 to 1.42, 0.74) | 0.88 (0.58 to 1.35, 0.57) | 0.58 (0.37 to 0.90, 0.02) | 1.03 (0.69 to 1.56, 0.88) | 0.63 (0.40 to 0.98, 0.04) | 1.38 (0.95 to 2.02, 0.09) | 1.00 (0.66 to 1.53, 0.98) |
49–69 | 1.15 (0.98 to 1.36, 0.08) | 1.00 (0.85 to 1.17, 0.98) | 0.91 (0.76 to 1.09, 0.29) | 1.04 (0.88 to 1.23, 0.63) | 1.06 (0.90 to 1.26, 0.49) | 1.02 (0.87 to 1.21, 0.77) | 0.99 (0.83 to 1.18, 0.92) |
70+ | 1.02 (0.94 to 1.10, 0.67) | 1.12 (1.03 to 1.22, 0.004) | 1.18 (1.10 to 1.29, <0.001) | 1.26 (1.16 to 1.36, <0.001) | 1.14 (1.05 to 1.24, 0.002) | 1.20 (1.10 to 1.30, <0.001) | 1.20 (1.11 to 1.31, <0.001) |
Risk of death in-hospital excluding COVID-19-related attendances for the five most common diagnosed expected to be stable without COVID-19 pandemic | |||||||
Schizophrenia | NA | NA | NA | NA | NA | NA | NA |
COPD exacerbation | 1.06 (0.47 to 2.45, 0.88) | 0.49 (0.19 to 1.26, 0.14) | 0.68 (0.23 to 2.04, 0.49) | 0.63 (0.23 to 1.70, 0.36) | 0.36 (0.12 to 1.12, 0.08) | 1.47 (0.59 to 3.68, 0.41) | 0.49 (0.15 to 1.59, 0.24) |
Hip fracture | 1.08 (0.28 to 4.15, 0.90) | 0.73 (0.17 to 3.10, 0.67) | 1.45 (0.13 to 16.7, 0.77) | 0.75 (0.10 to 5.40, 0.76) | 1.09 (0.09 to 12.50, 0.95) | 0.54 (0.29 to 5.83, 0.50) | 1.31 (0.29 to 5.84, 0.73) |
Myocardial Infarction | 1.13 (0.27 to 4.60) | NA | 1.35 (0.21 to 8.72) | 0.33 (0.04 to 3.2) | 4.53 (0.81 to 25.20) | 2.41 (0.50 to 11.73) | 0.81 (0.18 to 3.72) |
Urinary tract infection | NA | NA | NA | NA | NA | NA | NA |
The incidence rate of attendances in the control period from 2017 to 2019 was used as reference.
NA signifies numbers that could not be calculated due to too few events.
The ‘five most stable diagnoses’ designate the 5 of 29 prespecified diagnoses we expected to remain stable during a pandemic.
COPD, chronic obstructive pulmonary disease; COVID, SARS-CoV2 virus disease; MRR, mortality rate ratio.